Mediar Therapeutics nabbed $85 million to get in the clinic next year with its first antibody meant to modulate fibrosis, hence the biotech’s name (in the form of Spanish).
The Cambridge, MA startup aims to create more precise treatments for fibrosis by going after targets associated with disease severity and that can be measured in plasma, CEO Rahul Ballal told Endpoints News. Ballal said the biotech is exploring a number of indications as fibrosis spans many areas: liver, lung, renal and cardiac.
Access the article on endpts.com (paywall)